Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab in advanced basal cell carcinoma
NCT03132636Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2017
- Primary completion
- May 2021
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 10
01
Overview
Phase 2, open-label trial of cemiplimab in basal cell carcinoma (BCC) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Objective Response Rate by ICR up to 46 months. Started Jun 2017; status: completed.
02
Drugs
cemiplimab
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT03132636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03132636.